Basic Information of Febuxostat Intermediates 161798-03-4
CAS No. of key intermediates: 161798-03-4
Other Names: Ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methyl thiazole-5-carboxylate
Appearance: Yellow powder, Yellow powder
Usage of Febuxostat Intermediates 161798-03-4
Febuxostat Intermediates for the Treatment of Gout Chronic Hyperuricemia Blood Syndrome.
Gout occurs because the body produces excessive uric acid and decreased renal clearance, uric acid accumulation in the body, resulting in urate crystals in the joints and organs deposition. Therefore, gout treatment is usually taken by means of: uric acid excretion and inhibition of uric acid production, and the use of appropriate measures to improve the symptoms. In vivo uric acid production is related to purine metabolism. In the final purine metabolism step, hypoxanthine produces xanthine under the action of xanthine oxidoreductase (XOR) and further generates uric acid, and the activity of inhibiting this enzyme can be effectively reduced The formation of uric acid. Febuxostat is the most recently developed XOR inhibitor in the world. It effectively treats ventilatory diseases by acting on the oxidase highly selectively, reducing uric acid synthesis in the body and lowering uric acid concentration. For 30 years, allopurinol has been clinically the only drug used to inhibit uric acid production. It is widely used clinically as a gold treatment for gout and has achieved good results in the treatment of gout. Compared with allopurin, febuxostat has obvious advantages:
(1) Allopurinol only inhibited the reduced XOR, while the non-busulfan significantly inhibited the XOR of the oxidized and the reduced XOR. Therefore, its effect of lowering uric acid was stronger and longer;
(2) Since allopurinol is a purine analogue, the effect of other enzymatic activities involving purine and pyridine metabolism is inevitably caused. Therefore, allopurinol treatment, the need for repeated high-dose administration to maintain a high drug level. As a result, serious and even fatal adverse reactions due to drug accumulation are also caused. The non-Boxetan non-purine XOR inhibitors, so have better safety.